Position:
Clinical Professor
Division:
Hematology
Research Interests:

Hematopoietic stem cell transplantation, Myeloid leukemias

 

Education:
Nottingham University Medical School Medical Sciences, B Med Sci
Nottingham University Medical School Medicine, BM, BS
Recent Publications:

•Greenwood MJ, Seftel MD, Richardson C, Barbaric D, Barnett MJ, Bruyere H, Forrest DL, Horsman DE, Smith C, Song K, Sutherland HJ, Toze CL, Nevill TJ, Nantel SH & Hogge DE. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma 47: 1245-1252, 2006.
•Johny A, Song KW, Nantel SH, Lavoie JC, Toze CL, Hogge DE, Forrest DL, Sutherland HJ, Le A, Nitta JY, Barnett MJ, Smith CA, Shepherd JD & Nevill TJ. Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide. Biol Blood Marrow Transplant 12: 480-489, 2006.
•Laneuville PJ, Barnett MJ, Belanger R, Couban S, Forrest DL, Roy D-C & Lipton JH. Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia. Curr Onc 13: 1-20, 2006.
•Lin Y, Bruyere H, Horsman DE, Pantzar T, Barnett MJ, Hogge DE, Nevill TJ, Nantel SH, Sutherland HJ, Toze CL, Shepherd JD, Lavoie JC, Song KW, Smith CA & Forrest DL. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genet Cytogenet 170: 16-23, 2006.
•Song KW, Barnett MJ, Gascoyne RD, Horsman DE, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Voss NJ, Toze CL & Connors JM. Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol 133: 634-637, 2006.
•Dalal BI, Bruyere H & Barnett MJ. Significance of persistent Auer rods and cytogenetic abnormality after first cycle of therapy for acute promyelocytic leukaemia. Br J Haematol 137, 385, 2007.
•Gallagher G, Chhanabhai M, Song KW & Barnett MJ. Unusual presentation of precursor T-cell lymphoblastic lymphoma: involvement limited to breasts and skin. Leuk Lymphoma 48(2): 428-430, 2007.
•Halim TY, Song KW, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL & Lavoie JC. Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia. Ann Oncol 18: 1246-52, 2007.
•Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ & Song KW. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 13: 925-931, 2007.
•Song KW, Barnett MJ, Gascoyne RD, Chhanabhai M, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Voss NJ & Connors JM. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. Ann Oncol 18: 535-40, 2007.
•Leitch HA, Leger CS, Goodman TA, Wong KK, Wong DHC, Ramadan KM, Rollins MD, Barnett MJ, Galbraith PF & Vickars LM. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leukemia 2:205-211, 2008.
•Nevill TJ, Hogge DE, Toze CL, Nantel SH, Power MM, Abou-Mourad YR, Song KW, Lavoie JC, Forrest DL, Barnett MJ, Shepherd JD, Nitta JY, Wong S, Sutherland HJ & Smith CA. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML. Bone Marrow Transplant 42: 659-666, 2008.
•Owen C, Barnett MJ & Fitzgibbon J. Familal myelodysplasia and acute myeloid leukemia – a review. Br. J Haematol 140:123-132, 2008.
•Owen CJ, Toze CL, Koochin A, Forrest DL, Smith CA, Stevens JM, Jackson SC, Poon M-C, Sinclair GD, Leber B, Johnson PRE, Macheta A, Yin JAL, Barnett MJ, Lister TA & Fitzgibbon J. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 112: 4639-4645, 2008.
•Ramadan KM, Connors JM, Al-Tourah AJ, Song KW, Gascoyne RD, Barnett MJ, Nevill TJ, Shepherd JD, Nantel SH, Sutherland HJ, Forrest DL, Hogge DE, Lavoie JC, Abou-Mourad YR, Chhanabhai M, Voss NJ, Brinkman RR, Smith CA & Toze CL. Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplant 42: 601-608, 2008.
•Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, Nevill TJ, Shepherd JD, Nantel SH, Toze CL, Sutherland HJ, Song KW, Lavoie JC, Power MM, Abou-Mourad Y & Smith CA. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 33: 271-275, 2009.
•Maurer-Spurej E, Labrie A, Pittendreigh C, Chipperfield K, Smith C, Heddle N, Liu Y, Yi Q-L & Barnett M. Platelet quality measured with dynamic light scattering correlates with transfusion outcome in hematologic malignancies. Transfusion 49:2276-2284, 2009.
•Wright MP, Shepherd JD, Barnett MJ, Nantel SH, Sutherland HJ, Toze CL, Hogge DE, Nevill TJ, Song KW, Abou Mourad YR, Narayanan S, Power MM, Smith CA, Forrest DL. Response to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia Relapsing in Chronic and Advanced Phase Following Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2009 Epub ahead of print].
•Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, Nevill TJ, Shepherd JD, Nantel SH, Toze CL, Sutherland HJ, Song KW, Lavoie JC, Power MM, Abou-Mourad Y & Smith CA. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 33: 271-275, 2009.
•Maurer-Spurej E, Labrie A, Pittendreigh C, Chipperfield K, Smith C, Heddle N, Liu Y, Yi Q-L & Barnett M. Platelet quality measured with dynamic light scattering correlates with transfusion outcome in hematologic malignancies. Transfusion 49:2276-2284, 2009.
•Abou-Mourad YR, Lau BC, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Lavoie JC. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant. 2010 Feb;45(2):295-302.
•Leitch HA, Chase JM, Goodman TA, Ezzat H, Rollins MD, Wong DH, Badawi M, Leger CS, Ramadan KM, Barnett MJ, Foltz LM, Vickars LM. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Hematol Oncol. 2010 Mar;28(1):40-8.
•Wright MP, Shepherd JD, Barnett MJ, Nantel SH, Sutherland HJ, Toze CL, Hogge DE, Nevill TJ, Song KW, Abou Mourad YR, Narayanan S, Power MM, Smith CA, Forrest DL. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010 May;16(5):639-46.